247 related articles for article (PubMed ID: 10037246)
1. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.
Van den Berghe G; Wouters P; Bowers CY; de Zegher F; Bouillon R; Veldhuis JD
Eur J Endocrinol; 1999 Jan; 140(1):17-22. PubMed ID: 10037246
[TBL] [Abstract][Full Text] [Related]
2. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Gouwy S; Stockman W; Weekers F; Schetz M; Lauwers P; Bouillon R; Bowers CY
Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
[TBL] [Abstract][Full Text] [Related]
3. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
Van den Berghe G; de Zegher F; Baxter RC; Veldhuis JD; Wouters P; Schetz M; Verwaest C; Van der Vorst E; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Feb; 83(2):309-19. PubMed ID: 9467533
[TBL] [Abstract][Full Text] [Related]
5. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
6. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Iranmanesh A; Veldhuis JD; Bouillon R
Clin Endocrinol (Oxf); 2002 May; 56(5):655-69. PubMed ID: 12030918
[TBL] [Abstract][Full Text] [Related]
7. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
[TBL] [Abstract][Full Text] [Related]
8. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
Shah N; Evans WS; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
[TBL] [Abstract][Full Text] [Related]
9. Effect of simultaneous administration of GHRH (1-40) and TRH on GH, PRL and TSH secretion in normal man.
Giusti M; Lomeo A; Mazzocchi G; Torre R; Monachesi M; Sessarego P; Attanasio R; Giordano G
J Endocrinol Invest; 1986 Dec; 9(6):497-501. PubMed ID: 3106459
[TBL] [Abstract][Full Text] [Related]
10. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
[TBL] [Abstract][Full Text] [Related]
11. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
[TBL] [Abstract][Full Text] [Related]
12. Enhanced GH responses to combined administration of GHRP and GHRH in patients with acromegaly.
Hanew K; Utsumi A; Sugawara A; Shimizu Y; Abe K
J Clin Endocrinol Metab; 1994 Mar; 78(3):509-12. PubMed ID: 8126120
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.
Bowers CY; Reynolds GA; Durham D; Barrera CM; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1990 Apr; 70(4):975-82. PubMed ID: 2108187
[TBL] [Abstract][Full Text] [Related]
14. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion.
Alba-Roth J; Müller OA; Schopohl J; von Werder K
J Clin Endocrinol Metab; 1988 Dec; 67(6):1186-9. PubMed ID: 2903866
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
Bowers CY; Granda-Ayala R
Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
[TBL] [Abstract][Full Text] [Related]
16. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
[TBL] [Abstract][Full Text] [Related]
17. Effects of acute infusion of erythropoietin on paradoxical responses of growth hormone to thyrotropin-releasing hormone in acromegalic patients.
Díez JJ; Iglesias P; Sastre J; Gómez-Pan A
Eur J Endocrinol; 2000 Aug; 143(2):203-11. PubMed ID: 10913939
[TBL] [Abstract][Full Text] [Related]
18. Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women.
Veldhuis JD; Evans WS; Bowers CY
J Clin Endocrinol Metab; 2002 Feb; 87(2):859-66. PubMed ID: 11836333
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.
Van den Berghe G; Wouters P; Weekers F; Mohan S; Baxter RC; Veldhuis JD; Bowers CY; Bouillon R
J Clin Endocrinol Metab; 1999 Apr; 84(4):1311-23. PubMed ID: 10199772
[TBL] [Abstract][Full Text] [Related]
20. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.
Shah N; Evans WS; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2000 Aug; 85(8):2649-59. PubMed ID: 10946861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
